Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD study

Londoño, María-Carlota; Riveiro‐Barciela, Mar; Ahumada, Adriana; Muñoz‐Gómez, Raquel; Roget, Mercè; Devesa-Medina, María J.; Serra, Miguel; Navascués, C.A.; Baliellas, Carme; Aldámiz‐Echevarría, Teresa; Gutiérrez, María Luisa; Polo-Lorduy, Benjamín; Carmona, Isabel; Benlloch, Salvador; Bonet, Lucía; García-Samaniego, Javier; Jiménez‐Pérez, Miguel; Sánchez, S. Morán; Castro, Ángeles; Delgado, Manuel; Gea-Rodríguez, Francisco; Martín-Granizo, Ignacio; Montes, Marisa; Morano, Luís; Castaño, Manuel; Santos, Ignacio; Laguno, Montserrat; Losa, Juan Emilio; Montero, Marta; Rivero, Antonio; Álvaro, Cristina de; Manzanares, Amanda; Mallolas, Josép; Barril, Guillermina; González‐Parra, Emilio; Garcı́a-Buey, Luisa

doi:10.1371/journal.pone.0221567

Cited by 7 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Across 3817 patients, only 35 were on peritoneal dialysis. 9 , 22 , 23 , 24 , 26 , 29 , 30 , 31 , 34 , 37 , 38 , 39 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 The s...…”

Section: Ckd G4–g5ndunclassified

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Balk¹,

Adam²,

Jadoul³

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

Section: Ckd G4–g5ndunclassified

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Balk¹,

Adam²,

Jadoul³

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

“…Although anemia, asthenia and pruritus were the most common adverse events during treatment, regimens were also well tolerated in these patients. High SVR12 rate obtained (92.6%) is particularly noteworthy [18]. The above-mentioned reports indicated high cure rates and favorable safety profiles for the drugs in PD patients.…”

Section: Discussionmentioning

confidence: 59%

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient

Chen

et al. 2020

Renal Failure

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is known to affect long-term patient survivals. Elbasvir/grazoprevir (EBR/GZR) has shown a high cure rate in hemodialysis patients with HCV infection. However, the combination is rarely used in peritoneal dialysis patients. Herein, we report a case of successful treatment with EBR/GZR in a peritoneal dialysis patient with HCV genotype 1 b infection. A 54-year-old woman on peritoneal dialysis(PD) with HCV genotype 1 b infection had been received EBR (100 mg) and GZR (50 mg) once daily for 12 weeks. Hepatitis C virus RNA was undetectable 4 weeks after the treatment. She achieved a sustained virological response at 12 weeks after the end of treatment. Only fatigue was reported as side effect during the treatment. Thus, elbasvir/grazoprevir was effective and safe in this PD patient with HCV genotype 1 b infection.

show abstract

“…In the case of treatment with ombitasvir, paritaprevir, ritonavir and dasabuvir, SVR rates reported in clinical trials ranged from 91% to 100%, depending on the degree of fibrosis and HCV genotype (16)(17)(18). In a large, real-life trial in Spain, SVR rates in patients with chronic kidney disease were 86.7% in patients with stage IIIB, 95% in patients with stage IV and 93% in patient with stage V (19). There were 10 reported non-SVR, one of which was classified as virological failure.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients

Droc

Istrate

Mercan-Stanciu

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: The aim of this study was to determine the safety and efficacy of a direct-acting antiviral treatment, ombitasvir/paritaprevir/ritonavir and dasabuvir, without ribavirin, in a real-life setting. Patients and Methods: We performed a prospective observational study including 108 patients undergoing hemodialysis for endstage kidney disease, referred to our clinic for antiviral therapy for chronic hepatitis C virus infection. Patients received treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, for 12 weeks. Sustained virologic response (SVR) was defined as undetectable viremia at 12 weeks after the end of therapy. For safety analysis, we monitored serum levels of hemoglobin, albumin, total bilirubin, alanineaminotransferase and aspartate-aminotransferase at the beginning and end of therapy, as well as at SVR. Verbal Numeric Rating Scale was used to assess the presence of nausea, headaches and fatigue. Results: We noted a high prevalence of diabetic and hypertensive nephropathy as the underlying cause of chronic kidney disease. Most of the patients had F2 and F3 liver fibrosis (32.40% and 34.25%, respectively). The SVR rate was 96.2% (103/107 patients).We recorded an unrelated death after the completion of antiviral therapy. We found increased levels of nausea, headaches and fatigue at the end of therapy compared to at initiation, The presence and degree of symptoms did not correlate with the underlying cause of renal disease (p=0.72) nor with the degree of fibrosis (p=0.08). Minimal increases in transaminases and bilirubin were recorded at the end of treatment, with no statistical significance. Conclusion: Oral antiviral therapy with ombitasvir/paritaprevir/ritonavir and dasabuvir can be safely used in hemodialysis patients, with similar response rates compared to the general population.Hepatitis C virus (HCV) infection is a major cause of mortality and morbidity both in the general population and in the population represented by patients in hemodialysis programs. The latter have an increased risk of developing many complications, and thus represent the main target for the eradication of HCV infection. Hemodialysis in supporting patients with end-stage renal disease unfortunately carries a risk for hepatitis C infection. The incidence of HCV infection among hemodialysis patients is higher compared to the general population in Europe, with variations between different regions of the continent; for example, in Romania both the incidence and the prevalence of the infection are still at an increased rate in chronic hemodialysis patients (1).There is currently a wide range of therapeutic resources against HCV, represented by interferon-free, direct-acting antiviral (DAA) regimens including the daclatasvir plus asunaprevir dual regimen, ledipasvir/sofosbuvir combination, ombitasvir/paritaprevir/ritonavir combination, elbasvir plus grazoprevir dual regimen, and glecaprevir/pibrentasvir combination. Current European guidelines recommend the use of DAAs as early as possible in all patients with a...

show abstract

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD study

Cited by 7 publications

References 22 publications

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient

Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients

Contact Info

Product

Resources

About